Nemes Rush Group LLC Buys 11,440 Shares of AbbVie Inc. $ABBV

Nemes Rush Group LLC increased its position in AbbVie Inc. (NYSE:ABBV) by 342.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,780 shares of the company’s stock after acquiring an additional 11,440 shares during the quarter. Nemes Rush Group LLC’s holdings in AbbVie were worth $2,743,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ABBV. Pettyjohn Wood & White Inc. increased its stake in shares of AbbVie by 1.5% in the second quarter. Pettyjohn Wood & White Inc. now owns 47,363 shares of the company’s stock worth $8,792,000 after purchasing an additional 698 shares in the last quarter. Private Management Group Inc. boosted its holdings in AbbVie by 1,021.9% in the 2nd quarter. Private Management Group Inc. now owns 32,961 shares of the company’s stock worth $6,118,000 after buying an additional 30,023 shares during the period. Cowa LLC increased its stake in AbbVie by 6.6% in the 2nd quarter. Cowa LLC now owns 5,286 shares of the company’s stock worth $981,000 after buying an additional 329 shares in the last quarter. WealthBridge Capital Management LLC raised its holdings in AbbVie by 2.1% during the second quarter. WealthBridge Capital Management LLC now owns 12,800 shares of the company’s stock valued at $2,376,000 after acquiring an additional 262 shares during the period. Finally, New World Advisors LLC purchased a new position in shares of AbbVie in the second quarter valued at about $303,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 2.9%

NYSE ABBV opened at $236.12 on Friday. The stock has a 50 day moving average price of $226.81 and a 200-day moving average price of $205.35. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The company has a market capitalization of $417.31 billion, a P/E ratio of 112.44, a P/E/G ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the prior year, the firm earned $3.00 earnings per share. AbbVie’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is 524.24%.

Analysts Set New Price Targets

ABBV has been the subject of several research analyst reports. Wells Fargo & Company increased their target price on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. UBS Group increased their price objective on shares of AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a report on Friday, November 7th. JPMorgan Chase & Co. lifted their price objective on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Bank of America upped their target price on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Finally, Scotiabank began coverage on shares of AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $241.85.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.